Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

NCT02639026 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Metastatic
Melanoma
Non Small Cell Lung Cancer (NSCLC)
Breast Cancer
Pancreatic Cancer

Interventions

RADIATION: Radiotherapy
DRUG: MEDI4736
DRUG: Tremelimumab

Sponsor

Abramson Cancer Center at Penn Medicine